Signs that BNT162b2 could be more effective in older age groups led companies to switch lead candidates, and they now head into a pivotal late-stage study.
Pfizer Inc. and BioNTech SE have switched to their ‘backup’ COVID-19 vaccine candidate after finding that it could provide a greater T cell immune response in older in patients and greater tolerability.
The companies will now take their BNT162b2 vaccine candidate into the Phase II/III study, rather than BNT162b1, its closely related...
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
